Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy

International Journal of Cancer

Volumn 107, Issue 2, 2003, Pages 303-308

  Tsuji, Eiichi ^a   Hiki, Naoki ^a   Nomura, Sachiyo ^a   Fukushima, Ryoji ^b   Kojima, Jun Ichi ^a   Ogawa, Toshihisa ^a   Mafune, Ken Ichi ^a   Mimura, Yoshikazu ^a   Kaminishi, Michio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bacterial endotoxin translocation; Cancer chemotherapy; Intestinal mucosa

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOTOXIN; FLUOROURACIL; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRACT FUNCTION; INFLAMMATION; INTESTINE; INTESTINE MUCOSA; LYMPH NODE; MALE; MESENTERY LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; TOTAL PARENTERAL NUTRITION; VEIN CATHETERIZATION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL TRANSLOCATION; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; FLUOROURACIL; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; NEOPLASMS; PARENTERAL NUTRITION, TOTAL; RATS; RATS, WISTAR; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141523065     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11196     Document Type: Article

References (35)

1. Stewart FM, Temeles D, Lowry P, Thraves T, Grosh WW, Quesenberry PJ. Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation. Blood 1993;81:2283-9.
2. Spijkervet FK, Sonis ST. New frontiers in the management of chemotherapy-induced mucositis. Curr Opin Oncol 1998;10(Suppl 1): S23-7.
3. Tisdale MJ. Cancer cachexia. Anticancer Drugs 1993;4:115-25.
4. Dikken C, Sitzia J. Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. J Clin Nurs 1998;7:371-9.
5. Katona C, Kralovanszky J, Rosta A, Pandi E, Fonyad G, Toth K, et al. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients. Oncology 1998;55:468-74.
6. Nagata H, Koike A, Kojima T, Ohiwa Y, Miwa M, Inamura Y, et al. Efficacy of the treatment of gastric cancer as neo-adjuvant chemotherapy of 48 hour continuous intravenous infusion of 5-fluorouracil (5-FU) with leucovorin (LV). Gan To Kagaku Ryoho 1993;20:2049-52.
7. White RS, Fuqua WB, Barrett O Jr. The effect of 5-fluorouracil on small bowel mucosa. J Surg Oncol 1971;3:501-6.
8. Fujita F, Fujita M, Sakamoto Y, Taguchi T. Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice. Gan To Kagaku Ryoho 1993;20:215-21.
9. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979;23:403-11.
10. Fujita F, Fujita M, Fujita M, Sakamoto Y. Combination chemotherapy of BOF-A2, a new 5-FU derivative, with various anticancer agents against human cancer xenografts in nude mice. Gan To Kagaku Ryoho 1994;21:1619-25.
11. Villar-Grimalt A, Aranda E, Massuti B, Belon J, Anton A. Jimeno JM, et al. Phase II study with iododoxorubicin in measurable advanced colorectal adenocarcinoma: effective rescue using weekly high-dose 5-fluorouracil (WFU)-Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD), Work Group of SEOM (Spanish Medical Oncology Society). Tumori 1994;80:124-7.
12. Bagrij T, Kralovanszky J, Gyergyay F, Kiss E, Peters GJ. Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil. Anticancer Res 1993;13:789-93.
13. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT. Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-4.
14. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
15. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991;5:338-43.
16. Kulander L, Pauksens K, Venge P. Soluble adhesion molecules, cytokines and cellular markers in serum in patients with acute infections. Scand J Infect Dis 2001;33:290-300.
17. Bellomo R. The cytokine network in the critically ill. Anaesth Intens Care 1992;20:288-302.
18. Krabbe KS, Bruunsgaard H, Hansen CM, Moller K, Fonsmark L, Qvist J, et al. Aging is associated with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol 2001;8:333-8.
19. Hiki N, Berger D, Buttenschoen K, Boelke E, Seidelmann M, Strecker W, et al. Endotoxemia and specific antibody behavior against different endotoxins following multiple injuries. J Trauma 1995;38:794-801.
20. Buttenschoen K, Buttenschoen DC, Berger D, Vasilescu C, Schafheutle S, Goeltenboth B, et al. Endotoxemia and acute-phase proteins in major abdominal surgery. Am J Surg 2001;181:36-43.
21. Hiki N, Berger D, Prigl C, Boelke E, Wiedeck H, Seidelmann M, et al. Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria. Infect Immun 1998;66:1135-41.
22. Tamion F, Richard V, Lyoumi S, Daveau M, Bonmarchand G, Leroy J, et al. Gut ischemia and mesenteric synthesis of inflammatory cytokines after hemorrhagic or endotoxic shock. Am J Physiol 1997;273:G314-21.
23. Chen YM, Whang-Peng J, Liu JM, Kuo BI, Wang SY, Tsai CM, et al. Serum cytokine level fluctuations in chemotherapy-induced myelo-suppression. Jpn J Clin Oncol 1996;26:18-23.
24. Loehry CA, Croft DN, Singh AK, Creamer B. Cell turnover in the small intestinal mucosa: an appraisal of cell loss. Gut 1969;10:13-6.
25. Le JM, Jan Vilcek. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987;56:234-48.
26. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwywe S, Dinarello CA, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318:1481-6.
27. Van Devender BSJH, Buller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-6.
28. Warren RS, Starnes HF, Gabrilove JL, Oettgen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987;122:1396-400.
29. Castell JV, Andus T, Kunz D, Heinrich PC. Interleukin-6: the major regulator of acute-phase protein synthesis in man and rat. Ann NY Acad Sci 1989;557:87-103.
30. Ray A, Tatter SB, Santhanam U, Helfgott DC, May LT, Sehgal PB. Regulation of expression of interleukin-6. Ann NY Acad Sci 1989;557:353-62.
31. Buttenschoen K, Berger D, Hiki N, Strecker W, Seidelmann M, Beger HG. Plasma concentrations of endotoxin and antiendotoxin antibodies in patients with multiple injuries: a prospective clinical study. Eur J Surg 1996;162:853-60.
32. Hiki N, Berger D, Mimura Y, Frick J, Dentener MA, Buurman WA, et al. Release of endotoxin-binding proteins during major elective surgery: role of soluble CD14 in phagocytic activation. World J Surg 2000;24:499-506.
33. Bolke E, Jehle PM, Orth K, Steinbach G, Hannekum A, Storck M. Changes of gut barrier function during anesthesia and cardiac surgery. Angiology 2001;52:477-82.
34. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989;170:1627-33.
35. Van Deventer SJH, Buller HR, Ten Cate JW, Sturk A, Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet 1988;19:605-8.